Explore Stanford technologies available for licensing:

Current immunotherapies for Type 1 diabetes (T1D), such as anti-thymocyte globulin (ATG) and anti-CD3 monoclonal antibodies, have several limitations.

Researchers at Stanford University have found that upregulating cathelicidin gene expression can improve the efficacy of a wide variety of treatments as an adjunct therapy.

Researchers from Stanford University and the Technical University of Munich (TUM) propose a new approach for treating Type 2 Diabetes (T2D) by targeting the cathelicidin gene expression pathway.

Disease indication - Type 1 and Type 2 Diabetes

Drug format - Peptide hormones (combination of amylin analogues and insulin analogues)

Drug class - Novel formulation with designer excipient for improved/simplified delivery

Researchers at Stanford have found that applying pressure to macroencapsulation can enhance insulin transport from encapsulated islet beta cells to surrounding tissue and assist in glucose metabolism in type 1 diabetes (T1D) patients.